Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, June 1999, p. 1358-1361, Vol. 43, No. 6
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Serine Protease Inhibitors Block Invasion of Host
Cells by Toxoplasma gondii
V.
Conseil,
M.
Soête, and
J. F.
Dubremetz*
Unité 42 INSERM. IBL, Institut Pasteur
de Lille, 59019 Lille Cedex, France
Received 16 November 1998/Returned for modification 1 February
1999/Accepted 19 March 1999
 |
ABSTRACT |
We investigated the effect of protease inhibitors on the asexual
development of the protozoan parasite Toxoplasma gondii. Among the inhibitors tested only two irreversible serine protease inhibitors, 3,4-dichloroisocoumarin and
4-(2-aminoethyl)-benzenesulfonyl fluoride, clearly prevented invasion
of the host cells by specifically affecting parasite targets in a
dose-dependent manner, with 50% inhibitory concentrations between 1 and 5 and 50 and 100 µM, respectively. Neither compound significantly
affected parasite morphology, basic metabolism, or gliding motility
within the range of the experimental conditions in which inhibition of
invasion was demonstrated. No partial invasion was observed, meaning
that inhibition occurred at an early stage of the interaction. These
results suggest that at least one serine protease of the parasite is
involved in the invasive process of T. gondii.
 |
INTRODUCTION |
Toxoplasma gondii is a
protozoan parasite responsible for toxoplasmosis, a disease affecting
humans and other warm-blooded animals. This parasite is highly
pathogenic during fetal development or upon immunosuppression (e.g., by
AIDS or immunosuppressive treatments). T. gondii is an
obligate intracellular parasite that can invade a wide range of cells,
and a key step in the infection is host cell invasion, which is a
prerequisite to parasite multiplication. Toxoplasmosis can be cured in
various ways, but existing treatments can lead to deleterious secondary
effects, and new therapeutic means are being investigated
(13). Proteases have been shown to be of critical importance
in development and host cell invasion for other apicomplexan parasites
(e.g., Plasmodium falciparum, Eimeria spp., and
Cryptosporidium parvum) and are therefore considered as
possible new therapeutic targets (1, 10-12, 19). Despite the highly conserved invasion process used by all apicomplexan parasites, little has been reported on the possible involvement of
proteases in invasion by T. gondii. The purpose of this
study was to assay a series of protease inhibitors for their effects on
T. gondii tachyzoite development to assess the potential
targeting of such enzymes in this parasite.
 |
MATERIALS AND METHODS |
Reagents.
All reagents were obtained from Sigma (St.
Quentin, France). Aprotinin, E64
[trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane] and 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF) solutions were prepared in sterile water. Pepstatin 3,4-dichloroisocoumarin (3,4-DCI), phenylmethane sulfonyl fluoride (PMSF), and di-isopropyl fluorophosphate (DIFP) were dissolved in dimethyl sulfoxide. All stock
solutions were stored at
20°C until they were used.
3[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) was
solubilized in sterile RPMI 1640 medium (without phenol red)
supplemented with 5% fetal calf serum (FCS) and stored at 4°C until
it was used. Poly-L-lysine was resuspended in sterile water
and stored at
20°C. Chlorophenol
red-
-D-galactopyranoside was obtained from Boehringer Mannheim.
Host cell culture and parasite propagation.
Vero cells
(African green monkey kidney cells) were grown in Dulbecco's modified
Eagle's medium (DMEM) containing 5% FCS (Boehringer), 2 mM glutamine,
and penicillin (1 U/ml)-streptomycin (1 µg/ml) at 37°C in a 5%
CO2 atmosphere. The T. gondii RH strain was used throughout this study, together with a stable
lacZ-transfected RH strain expressing a cytoplasmic
-galactosidase (provided by D. Soldati, Heidelberg, Germany). The
lacZ transfectant was used for parasite growth assays or
viability assays. The parasites were propagated either in Swiss mice or
in Vero cells. When developed in Vero cells, extracellular parasites
were recovered, passed twice through a 27-gauge needle, washed twice by
10 min of centrifugation at 1,000 × g in DMEM-5%
FCS, and resuspended in the same medium. Mouse-derived parasites were
recovered by peritoneal wash, passed twice through a 27-gauge needle,
washed twice by 1,000 × g centrifugation for 10 min in
DMEM-5% FCS, and then resuspended in the same medium before the
invasion assay or in DMEM without FCS for the motility assay.
Protease inhibitor assays.
Inhibitors or control solutions
(with DMSO or water) were prepared in DMEM-5% FCS and added to
parasite suspensions (vol/vol) 1 h before infection of Vero cells.
This preincubation was performed at 37°C in a 5% CO2
atmosphere with a 2 × 106/ml final parasite dilution
in both the growth and invasion assays. A final dilution of 25 × 106 tachyzoites/ml was used for the MTT assay.
Growth assay.
Vero cell monolayers grown on 96-well plates
were infected with 104 preincubated parasites either in the
presence of the inhibitor or after two washes and resuspension in
DMEM-5% FCS. Invasion was allowed for 1 h at 37°C in 5%
CO2 after 15 min of parasite sedimentation on ice. The
wells were then washed three times with medium and incubated for an
additional 24 h. The
-galactosidase activity was measured, as
previously described (23), by lysis of infected cells
followed by chlorophenol red-
-D-galactopyranoside assay. The absorbance was read at 540 nm with a microplate reader.
Invasion assay.
Pretreated tachyzoites (4 × 105) were added to confluent Vero cell monolayers grown on
glass slides in 2-cm2 wells. The parasite were permitted to
sediment for 15 min on ice, and then invasion was allowed at 37°C in
5% CO2 for 1 h. The wells were then washed twice in
phosphate-buffered saline, and the cells were fixed in methanol. The
slides were stained with eosin-methylene blue and mounted in Xam (BDH).
Quantitation was performed by counting the total number of
intracellular parasites present in 100 fields at ×100 magnification.
Viability assay.
Parasites or Vero cell monolayers were
treated in RPMI 1640 medium (without phenol red) supplemented with 5%
FCS, glutamine (2 mM), and antibiotics. Confluent cells or 2.5 × 106 tachyzoites per well in a 96-well plate were then
incubated for 1 h at 37°C in a 5% CO2 atmosphere,
and MTT (final concentration, 0.5 mg/ml) was then added for 1 h.
Solubilization of formazan formed by metabolic reduction of MTT was
obtained by using lysis buffer (2) (10% sodium dodecyl
sulfate-45% dimethyl formamide, adjusted to pH 4.5 with glacial
acetic acid). The absorbance was read at 540 nm with a microplate reader.
Motility assay.
Lab-Tek slides (Nunc) were coated with
poly-L-lysine (1 mg/ml) for 10 min at room temperature. The
slides were then washed three times in water and dried for 1 h.
Inhibitors or control solutions were added to freshly isolated
parasites resuspended in DMEM without FCS, and 6 × 105 parasites were added on
poly-L-lysine-coated slides for either 30 min or 1 h
at 37°C in 5% CO2 atmosphere. The slides were then fixed
with 4% formaldehyde for 30 min at room temperature. SAG1 trails left
on the slides by moving parasites were detected by incubation with
anti-SAG1 monoclonal antibody (5) and stained with
fluorescein isothiocyanate-labeled anti-mouse immunoglobulin G
antibodies. The slides were mounted in Mowiol, and gliding was quantified by measuring trail lengths, as described by Dobrowolski et
al. (7); parasites associated with trails were counted on 10 fields at ×100 magnification.
Statistical analysis.
Statistical analysis was performed
with the ANOVA program, and probit analysis representation was done
with the Sigma Plot program.
 |
RESULTS |
Identification of serine protease inhibitors specifically altering
T. gondii growth in culture.
A preliminary study of
the effect of protease inhibitors on T. gondii was performed
by using the
-galactosidase assay (growth assay) at 24 h
postinfection. This assay has been shown to reliably enumerate viable
parasites in a linear fashion based on
-galactosidase production
(23) and is an alternative to radioactive assay for the
identification of anti-T. gondii compounds (16).
Under these conditions, the treatment of extracellular tachyzoites with
pepstatin and E64 (up to 100 µM), which are inhibitors of aspartic
and cysteine proteases, respectively, did not alter parasite growth
(data not shown) while two irreversible serine protease inhibitors,
3,4-DCI and AEBSF, significantly altered T. gondii growth,
with 50% inhibitory concentrations (IC50s) between 1 and 5 and 50 and 100 µM, respectively (Fig.
1). When other serine protease inhibitors
were tested under similar conditions, no significant inhibitory effect
on parasite growth was detected in the same range of concentrations.
Among PMSF (up to 1 mM), aprotinin (up to 200 µM), and DIFP, only
DIFP showed some effect at 200 µM, which led to 34% inhibition of
-galactosidase activity compared to the control (data not shown).

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 1.
Inhibition of T. gondii growth by various
concentrations of 3,4-DCI and AEBSF measured by -galactosidase
assay. Extracellular tachyzoites were first pretreated for 1 h
with inhibitors, and then cell infection was permitted for 1 h in
the presence of inhibitors. Control values (C) were obtained after
treatments with medium supplemented with dimethyl sulfoxide or water
for DIC and AEBSF, respectively. Each value is the mean of three
experiments done in triplicate + the standard deviation. The
asterisks indicate the significant inhibitions compared with the
control: *, P < 0.05; **, P < 0.01.
|
|
The specific effect of 3,4-DCI and AEBSF on parasites was assessed by
pretreatment of host cells for 1 h. The cells were then
washed
before infection with untreated parasites. As shown in
Fig.
2,
3,4-DCI and AEBSF showed no
significant inhibition of
parasite growth under these conditions. When
the parasites were
treated for 1 h and washed twice before the
infection of Vero
cells, the measured

-galactosidase activities were
strongly reduced
compared to those of the untreated control and reached
the same
inhibitory values as those obtained when infection was
performed
in the presence of an inhibitor (Fig.
1 and
2).

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 2.
Effect of 3,4-DCI and AEBSF concentrations on T. gondii growth as measured by -galactosidase assay after a 1-h
treatment of host cells or extracellular tachyzoites before infection
in the absence of inhibitors. Each value is the mean of three
experiments done in triplicate + the standard deviation, expressed
as percentages of values (optical density [O.D.]) for control
treatment. The asterisks indicate the significant inhibitions compared
with the control: *, P < 0.05; **,
P < 0.01.
|
|
3,4-DCI and AEBSF effect on invasion process and intracellular
growth of T. gondii.
In order to identify the step of
parasite growth affected by 3,4-DCI or AEBSF, the inhibitors were
tested in an invasion assay. Both inhibitors dramatically decreased the
percentage of parasites successfully penetrating cells at
concentrations similar to those used for the growth assay (Fig.
3). Using the same inhibitor
concentrations, inhibition of invasion and growth were not
statistically different, confirming that 3,4-DCI and AEBSF affected the
invasion process. Moreover, the correlation coefficients
(R2) calculated for the inhibitors (0.976 and
0.996 for 3,4-DCI and AEBSF, respectively) strongly support linear
dose-dependent effects on the invasion process. The IC50s
calculated from linear plots (probit representation of the relative
percentage of inhibition of growth versus the logarithm of the drug
concentration) were 2.2 µM for 3,4-DCI and 67 µM for AEBSF. The
efficiency of inhibition of parasite growth was also analyzed with
serum-free medium. Under these conditions, the IC50s
decreased to 44 µM for AEBSF and 0.2 µM for 3,4-DCI. The effects of
the inhibitors were also dependent on the duration of pretreatment
(either 15 or 60 min). With minimal pretreatment time (15 min) for
parasite sedimentation, the IC50 was above 200 µM for
AEBSF and between 10 and 25 µM for 3,4-DCI (data not shown).

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 3.
Comparison of the effect of various concentrations of
3,4-DCI (A) and AEBSF (B) on T. gondii growth and host cell
invasion. Extracellular tachyzoites were pretreated for 1 h, and
cell infection was performed for 1 h. Each value is the mean of
three experiments (performed in triplicate) + the standard deviation,
expressed as percentages of values (optical density [O.D.]) for
control treatment. The asterisks indicate the significant inhibitions
compared with the control: *, P < 0.05; **,
P < 0.01.
|
|
To analyze a possible impairment of intracellular parasite growth,
infected cells (taken 4 h after invasion) were treated
for 1 h and

-galactosidase activity was measured 24 h later.
Under
these conditions, AEBSF had no inhibitory effect on parasite
growth in
the concentration range tested (up to 200 µM). In contrast,
3,4-DCI
demonstrated significant inhibition of parasite growth
(24.7%) at 25 µM (data not
shown).
Parasite integrity, viability, and motility.
We then tried to
characterize the inhibitory effect of 3,4-DCI and AEBSF on the invasion
process. Parasite morphology was unaffected: both propidium iodide
assay and electron microscopy analysis confirmed parasite integrity
after inhibitor treatments with the highest concentrations tested (data
not shown). Parasite viability was then evaluated by a tetrazolium salt
reduction assay. Microculture tetrazolium assays are widely applied to
quantify cell metabolic activity (2). Therefore, we used
such a test to evaluate the possible metabolic toxicity of the protease
inhibitors on parasites and host cells. We verified that MTT
colorimetric quantitation was a linear function of parasite or cell
number (not shown). When host cells were pretreated for 1 h with
inhibitors, no significant toxicity was observed with 3,4-DCI up to 50 µM or AEBSF up to 200 µM. Also, no significant toxicity to
parasites was observed with AEBSF in the same range of concentrations.
In contrast, a significant difference (P < 0.01) was
found between tachyzoites treated with over 25 µM 3,4-DCI and control
tachyzoites (leading to 19.7% inhibition of MTT reduction) (data not shown).
In order to determine whether 3,4-DCI and AEBSF could affect parasite
motility, we tested these inhibitors on parasite gliding
as described
above. Using 3,4-DCI at 10 µM, parasite gliding was
not affected
during a 30-min assay (conditions which in the invasion
assay to led
90% inhibition), whereas a 2-h assay (1 h of pretreatment
and 1 h
of gliding assay) significantly affected parasite motility
by
decreasing both the average trail distance (
P < 0.05)
and the
percentage of parasites associated with trails (
P < 0.01) (Fig.
4). In contrast, 200 µM AEBSF did not affect parasite gliding
in a 2-h assay (data not
shown).

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 4.
Time dependency effect of 3,4-DCI on tachyzoite gliding:
average trail distance (A) and percentage of tachyzoites associated
with trails (B). A gliding assay was performed with the inhibitor
either for 30 min with no pretreatment or for 1 h after 1 h
of pretreatment (2 h of treatment). The data presented are from a
representative experiment with a 3,4-DCI concentration (10 µM)
leading to 93.4% inhibition of invasion after a 30-min treatment.
|
|
Microscopic observation of cell monolayers fixed after interaction with
treated parasites showed no evidence of abortive invasion
(i.e.,
partial internalization of parasites, such as can be observed
by
fixation of the monolayer during normal invasion), suggesting
that
blocking occurs at an early stage of the
process.
 |
DISCUSSION |
The invasion process of T. gondii is still poorly
understood. Myosin-like chain kinase inhibitor (KT5926), myosin ATPase
inhibitor (butanedione monoxime), and cytochalasin D, all affecting the motility of the parasite (7, 8), and phospholipase
A2 inhibitors (14, 20, 21, 24) have been
described as inhibitors of invasion. Little information concerning
the proteases of T. gondii has been reported (4,
22), whereas the involvement of such enzymes and their potential
targeting have been more thoroughly explored in apicomplexan parasites
in the genera Plasmodium, Eimeria, and
Cryptosporidium (1, 10-12, 19). In the course of
this study we have first confirmed preliminary data previously reported by others (22); treatment of extracellular tachyzoites with pepstatin or E64 (protease inhibitors of aspartic and cysteine proteases, respectively) or aprotinin and PMSF (serine protease inhibitors) did not alter the invasion of host cells by
tachyzoites. New data were obtained with two other irreversible
serine protease inhibitors, 3,4-DCI and AEBSF, which dramatically
decreased penetration by tachyzoites of T. gondii
without altering their structural integrity. As host cell pretreatment
did not affect invasion, these results suggest that a parasite
enzyme(s) is the target of these inhibitors.
Harper et al. (15) have described 3,4-DCI as a general
protease inhibitor that reacts principally with a broad range of serine
proteases. This inhibitor is more potent and reacts more quickly than
the two other commonly used serine protease inhibitors, DIFP and PMSF
(17). All three of these inhibitors are hydrophobic reagents
that are extremely sensitive to hydrolysis. The difference in
reactivity among these compounds may explain the discrepancies in
efficiency. AEBSF is also a general serine protease inhibitor that is
soluble and stable in aqueous solution. In this case, the difference in
hydrophilic properties between AEBSF and 3,4-DCI may explain the
higher IC50 with AEBSF, if the target(s) of these inhibitors is intracellular. The inefficacy of aprotinin, a
macromolecular inhibitor, apart from its narrower range of specificity
(it is not a general serine protease inhibitor), could also reflect its inability to access the target(s) affected by 3,4-DCI and AEBSF. An
additional piece of evidence that the target is intracellular is that
invasion of treated parasites cannot be restored by using supernatant
recovered from the interaction between untreated parasites and cells.
The likely explanation is that the efficient inhibitors act inside the
parasites and that specificity, stability, and accessibility may
separately or collectively explain the heterogeneity of effects of the
serine protease inhibitors tested.
In order to evaluate the specificity of the effect on invasion versus a
possible more general toxic effect of the tested inhibitors, several
other assays were performed, including morphological examination, MTT
assay, and a gliding assay. MTT assays are colorimetric methods based
upon the reduction of tetrazolium salts: most cellular bioreduction of
MTT is associated with enzymes of the endoplasmic reticulum and
involves NADH and NADPH pyridine nucleotides (2). Thus, MTT
assay reveals the effect of an inhibitor on the basic metabolism of the
parasite. No significant effect of 3,4-DCI on this bioreduction was
found below 25 µM after a 1-h treatment (a condition leading to more
than 90% inhibition of invasion), but the effect increased progressively above this value. Therefore, 3,4-DCI can exert a general
toxicity on parasites, but the concentrations required exceed those
that cause significant reductions in invasion. This toxicity might
explain the effect of this reagent on intracellular parasite
development. In contrast, AEBSF had no effect on MTT reduction within
the range tested. These results lead us to conclude that both 3,4-DCI
and AEBSF act on enzyme(s) active during the invasion process.
Additionally, 3,4-DCI may exert an effect on another target(s) involved
in parasite metabolism at higher doses.
3,4-DCI and AEBSF are essentially protease inhibitors, but both
reagents can also inhibit several esterases (6, 17), because
the latter enzymes are mechanistically quite similar to serine
proteases. Therefore, one could wonder whether these proteinase inhibitors could affect phospholipase A2
(PLA2), which has been suggested to be involved in invasion
(14, 20, 21). However, AEBSF minimally inhibits
PLA2 from naja venom and porcine pancreas (6),
and treatment of host cells with either 3,4-DCI or AEBSF does not
affect infectivity, in contrast to 4-bromophenacyl bromide (a
specific PLA2 inhibitor previously tested
[14]). These observations tend to exclude these
enzymes as targets of the inhibitors characterized in the present study.
3,4-DCI and AEBSF also block invasion without inhibiting motility (as
monitored by the deposition of trails of surface proteins on a
substrate [8]), which suggests that the mechanism of
gliding is not the target of these inhibitors. However, a
prolonged exposure to 3,4-DCI can lead to an inhibitory effect on
parasite motility, which might be related to a deleterious effect of
this inhibitor on the basic metabolism of the parasite.
Host cell invasion requires parasite motility, followed by the
formation of a moving junction with the host cell, exocytosis of
secretory organelles involved in the alteration of the host cell
membrane, and the development of the parasitophorous vacuole (9). Since we have not found evidence of abortive invasion, our results suggest that an early stage of the process is affected by
these serine protease inhibitors, the most likely being the moving
junction-exocytosis step. These results can then be compared to other
observations of closely related apicomplexan parasites, such as
P. falciparum and Plasmodium chabaudi, in which a
serine protease has been reported to be involved in host cell membrane alteration before or during erythrocyte invasion. This serine protease
acts by cleaving an external loop of human erythrocyte band 3 and
glycophorin A (3, 18). Serine proteases have also been
suggested to be involved in host cell invasion by Eimeria and Cryptosporidium species (1, 10, 12).
Therefore, a common mechanism involving serine proteases during
invasion by apicomplexan parasites likely exists. This mechanism
represents a potential new target for chemotherapy of the diseases
caused by these pathogens.
 |
ACKNOWLEDGMENTS |
We thank Daniel Dive, Thierry Jouault, and John R. Barta for
helpful advice and critical review of the manuscript and Anne Loyens
and Cedric Cheminay for technical assistance.
This work was supported by ANRS (Agence Nationale de Recherches sur le SIDA).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Unité 42 INSERM. IBL, Institut Pasteur de Lille, 1 rue Calmette 59019 Lille
Cedex, France. Phone: (33) 320 871 173. Fax: (33) 320 871 158. E-mail: jean-francois.dubremetz{at}pasteur-lille.fr.
 |
REFERENCES |
| 1.
|
Adams, J. H., and G. R. Bushell.
1988.
The effect of protease inhibitors on Eimeria vermiformis invasion of cultured cells.
Int. J. Parasitol.
18:683-685[Medline].
|
| 2.
|
Berridge, M. V.,
A. S. Tan,
K. D. McCoy, and R. Wang.
1996.
The biochemical and cellular basis of the cell proliferation assays that use tetrazolium salts.
Biochemica
4:15-20.
|
| 3.
|
Braun Breton, C.,
T. Blisnick,
H. Jouin,
J. C. Barale,
T. Rabilloud,
G. Langsley, and L. H. Pereira Da Silva.
1992.
Plasmodium chabaudi p68 serine protease activity required for merozoite entry into mouse erythrocytes.
Proc. Natl. Acad. Sci. USA
89:9647-9651[Abstract/Free Full Text].
|
| 4.
|
Choi, W. Y.,
H. W. Nam, and J. H. Youn.
1989.
Characterization of proteases of Toxoplasma gondii.
Korean J. Parasitol.
27:161-170[Medline].
|
| 5.
|
Couvreur, G.,
A. Sadak,
B. Fortier, and J. F. Dubremetz.
1988.
Surface antigens of Toxoplasma gondii.
Parasitology
97:1-10.
|
| 6.
|
Dentan, C.,
A. D. Tselepis,
M. J. Chapman, and E. Ninio.
1996.
Pefabloc, 4-[2-aminoethyl] benzenesulfonyl fluoride, is a new, potent nontoxic and irreversible inhibitor of PAF-degrading acetylhydrolase.
Biochim. Biophys. Acta
1299:353-357[Medline].
|
| 7.
|
Dobrowolski, J. M.,
V. B. Carruther, and D. Sibley.
1997.
Participation of myosin in gliding motility and host cell invasion by Toxoplasma gondii.
Mol. Microbiol.
26:163-173[Medline].
|
| 8.
|
Dobrowolski, J. M., and D. Sibley.
1996.
Toxoplasma invasion of mammalian cells is powered by the actin cytoskeleton of the parasite.
Cell
84:933-939[Medline].
|
| 9.
|
Dubremetz, J. F.,
N. Garcia-Reguet,
V. Conseil, and M. N. Fourmaux.
1998.
Apical organelles and host-cell invasion by apicomplexa.
Int. J. Parasitol.
28:1007-1013[Medline].
|
| 10.
|
Forney, J. R.,
S. Yang,
C. Du, and M. C. Healey.
1996.
Efficacy of serine protease inhibitors against Cryptosporidium parvum infection in a bovine fallopian tube epithelial cell culture system.
J. Parasitol.
82:638-640[Medline].
|
| 11.
|
Forney, J. R.,
S. Yang, and M. Healey.
1996.
Protease activity associated with excystation of Cryptosporidium parvum oocyst.
J. Parasitol.
82:889-892[Medline].
|
| 12.
|
Fuller, A. L., and L. R. McDougald.
1990.
Reduction in cell entry of Eimeria tenella (coccidia) sporozoites by protease inhibitors, and partial characterization of proteolytic activity associated with intact sprozoites and merozoites.
J. Parasitol.
76:464-467[Medline].
|
| 13.
|
Georgiev, V. S.
1994.
Management of toxoplasmosis.
Drugs
48:179-188[Medline].
|
| 14.
|
Gomez Martin, J. E.,
A. Bonhomme,
M. Guenounou, and J. M. Pinon.
1996.
Role of interferon- against invasion by Toxoplasma gondii in a human monocytic cell line (THP1): involvement of the parasite's secretory phospholipase A2.
Cell. Immunol.
169:218-225[Medline].
|
| 15.
|
Harper, J. W.,
K. Hemmi, and J. C. Powers.
1985.
Reaction of serine proteases with substituted isocoumarins: discovery of 3,4-dichloroisocoumarin, a new general mechanism based serine protease inhibitor.
Biochemistry
24:1831-1841[Medline].
|
| 16.
|
McFadden, D. C.,
F. Seeber, and J. C. Boothroyd.
1997.
Use of Toxoplasma gondii expressing -galactosidase for colorimetric assessment of drug activity in vitro.
Antimicrob. Agents Chemother.
41:1849-1853[Abstract].
|
| 17.
|
Powers, J. C., and C. M. Kam.
1995.
Isocoumarin inhibitors of serine peptidases.
Methods Enzymol.
244:442-457.
|
| 18.
|
Roggwiller, E.,
M. E. Morales Bétoulle,
T. Blisnick, and C. Braun Breton.
1996.
A role for erythrocyte band 3 degradation by the parasite gp76 serine protease in the formation of the parasitophorous vacuole during invasion of erythrocytes by Plasmodium falciparum.
Mol. Biochem. Parasitol.
82:13-24[Medline].
|
| 19.
|
Rosenthal, P. J.
1998.
Proteases of malaria parasites: new targets for chemotherapy.
Emerg. Infect. Dis.
4:49-57[Medline].
|
| 20.
|
Saffer, L. D.,
S. A. Long Krug, and J. D. Schwartzman.
1989.
The role of phospholipase in host cell penetration by Toxoplasma gondii.
Am. J. Trop. Med. Hyg.
40:145-149.
|
| 21.
|
Saffer, L. D., and J. D. Schwartzman.
1991.
A soluble phospholipase of Toxoplasma gondii associated with host cell penetration.
J. Protozool.
38:454-460[Medline].
|
| 22.
|
Schwartzman, J. D., and L. Saffer.
1992.
How Toxoplasma gondii gets into and out of host cells.
Subcell. Biochem.
18:333-364[Medline].
|
| 23.
|
Seeber, F., and J. C. Boothroyd.
1996.
Escherichia coli -galactosidase as an in vitro and in vivo reporter enzyme and stable transfection marker in the intracellular protozoan parasite Toxoplasma gondii.
Gene
169:39-45[Medline].
|
| 24.
|
Thardin, J. F.,
C. M'Rini,
M. Beraud,
J. Vandaele,
M. F. Frisach,
M. H. Bessieres,
J. P. Seguela, and B. Pipy.
1993.
Eicosanoid production by mouse peritoneal macrophages during Toxoplasma gondii penetration: role of parasite and host cell phospholipases.
Infect. Immun.
61:1432-1441[Abstract/Free Full Text].
|
Antimicrobial Agents and Chemotherapy, June 1999, p. 1358-1361, Vol. 43, No. 6
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Lavine, M. D., Arrizabalaga, G.
(2008). Exit from Host Cells by the Pathogenic Parasite Toxoplasma gondii Does Not Require Motility. Eukaryot Cell
7: 131-140
[Abstract]
[Full Text]
-
Teo, C. F., Zhou, X. W., Bogyo, M., Carruthers, V. B.
(2007). Cysteine Protease Inhibitors Block Toxoplasma gondii Microneme Secretion and Cell Invasion. Antimicrob. Agents Chemother.
51: 679-688
[Abstract]
[Full Text]
-
Urban, S.
(2006). Rhomboid proteins: conserved membrane proteases with divergent biological functions.. Genes Dev.
20: 3054-3068
[Abstract]
[Full Text]
-
Bradley, P. J., Ward, C., Cheng, S. J., Alexander, D. L., Coller, S., Coombs, G. H., Dunn, J. D., Ferguson, D. J., Sanderson, S. J., Wastling, J. M., Boothroyd, J. C.
(2005). Proteomic Analysis of Rhoptry Organelles Reveals Many Novel Constituents for Host-Parasite Interactions in Toxoplasma gondii. J. Biol. Chem.
280: 34245-34258
[Abstract]
[Full Text]
-
Zhou, X. W., Blackman, M. J., Howell, S. A., Carruthers, V. B.
(2004). Proteomic Analysis of Cleavage Events Reveals a Dynamic Two-step Mechanism for Proteolysis of a Key Parasite Adhesive Complex. Mol. Cell. Proteomics
3: 565-576
[Abstract]
[Full Text]
-
Buitrago-Rey, R., Olarte, J., Gomez-Marin, J. E.
(2002). Evaluation of two inhibitors of invasion: LY311727 [3-(3-acetamide-1-benzyl-2-ethyl-indolyl-5-oxy)propane phosphonic acid] and AEBSF [4-(2-aminoethyl)-benzenesulphonyl fluoride] in acute murine toxoplasmosis. J Antimicrob Chemother
49: 871-874
[Abstract]
[Full Text]
-
Bannister, L. H.
(2001). Looking for the exit: How do malaria parasites escape from red blood cells?. Proc. Natl. Acad. Sci. USA
98: 383-384
[Full Text]
-
Derouin, F., Santillana-Hayat, M.
(2000). Anti-Toxoplasma Activities of Antiretroviral Drugs and Interactions with Pyrimethamine and Sulfadiazine In Vitro. Antimicrob. Agents Chemother.
44: 2575-2577
[Abstract]
[Full Text]
-
Carruthers, V. B., Sherman, G. D., Sibley, L. D.
(2000). The Toxoplasma Adhesive Protein MIC2 Is Proteolytically Processed at Multiple Sites by Two Parasite-derived Proteases. J. Biol. Chem.
275: 14346-14353
[Abstract]
[Full Text]
-
Miller, S. A., Binder, E. M., Blackman, M. J., Carruthers, V. B., Kim, K.
(2001). A Conserved Subtilisin-like Protein TgSUB1 in Microneme Organelles of Toxoplasma gondii. J. Biol. Chem.
276: 45341-45348
[Abstract]
[Full Text]